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Overview
 Question for consideration
 Historical perspective of Pre-exposure prophylaxis schedules
 Vaccine potency and immunogenicity
 Routes of administration
 Review of evaluated PrEP schedules
 Boosters and duration of immunogenicity
 Special Populations
For your consideration…
 Status quo
 3-dose, 3-4 week schedule [0,7, 21 or 28]
 Serological monitoring and boosters based on risk category
 Should a 2-dose, 1-week schedule [0,7] for rabies PrEP be recommended?
 Recommended routes of administration
 Special populations
• High risk categories: booster/serological monitoring?
• Immunocompromised: alternate schedules/serological monitoring?
 All rabies vaccines are FDA approved as 3-dose series for PrEP
Rabies PrEP Recommendations 
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Nerve Tissue Vaccines
Duck Embryo Vaccine
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*Timeline not to scale
Vaccine Potency
 Modern rabies vaccine highly potent
 WHO and ACIP recommend ≥2.5 IU potency
 Potency and immune response correlated up to 2.5IU / IM dose
• No significant association identified above 2.5IU (or 0.5IU / dose ID)
IM
ID
Sudarshan et al. (2005 and 2010).  Hum Vaccin. 
Kinetics of Rabies Vaccine Immune Response
Overduin et al. (2019) Vaccine
ID route
 Limited Studies beyond neutralizing antibody response
Neutralizing Antibody as Surrogate of Protection 
 0.5 IU/mL rabies neutralizing 
antibodies (RFFIT)
 Not a measure of protection
 Measure of adequate response
 Reliable detection limit 
 Correlation between antibody titer 
and survival
 Variability between species
 Adequate antibody response after 
primary vaccination and anamnestic 
response to challenge best 
surrogates
Rabies Virus Antibodies from Oral Vaccination as Correlate of Protection against Lethal 
Infection in Wildlife
Moore S, et al. (2017). Trop Med Infect Dis., 
Survived Challenge Succumbed
Vaccination Route
 ID globally recommended vaccination 
route since 1980s
 ACIP recommendation 1984-2008
 ID found more cost effective in most 
settings and dose sparing in supply 
limited settings
 No licensed single use ID packaging or 
multi-draw vials for rabies vaccine
 Injection safety not well studied in 
setting of rabies ID administration
 Cost effectiveness (ID v IM) relational to 
PrEP or PEP patient volume
Fishbein et al. (1987). JID, Hampson et al. (2011). PLoS NTD. 
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Pre-exposure Prophylaxis (PrEP) Schedules
 3-dose
 0, 7, 21/28*
 0, 3, 7
 2-dose
 0, 28
 0, 7**
 1-dose
 Childhood immunization schedules (typically 2-dose, 2-3 months apart)
 Most schedules evaluated by both IM and ID routes
*Current ACIP recommended schedule
**Recently recommended WHO schedule
2-dose, 1-week Schedule
 2018: Recommended WHO PrEP
Schedule (IM or ID)
 1 dose vaccine administered IM on 
days 0 and 7
 Primary response well documented
 Infer from existing 3-dose schedule
Recuenco et al. (2017) Vaccine
2-dose, 1-week Schedule
 Clinical Trials
 ID
 N=500
 100% adequate response at day 35
 2-dose group had significantly higher GMT 
at 1 year compared to 3-dose
 No difference in post-booster response at 
1 year
Soentjens et al. (2018) CID. 
[0, 7, 28]
Day 365 7 d. post booster
[0, 7]
Day 365 7 d. post booster
3.4 IU/mL
2.0 IU/mL
Duration of Immunogenicity - Evidence
 Follow-up typically less than 1 year
 Longer follow-up
 Mostly [0, 7, 21/28] schedules
 Few [0, 28]
 Primary response titer not effective at predicting duration of immunogenicity
 Titer at 1 year or post booster significantly associated with titer 2-7 years later
 Titers >30 IU/mL post 1 year booster associated with adequate response 5-10 years later
Booster
 Booster at 1 year associated 
[0,7,21/28]with long term 
immunogenicity
Pengsaa et al (2009) Ped Infect Dis Jrnl
Booster Response
 Anamnestic response nearly universal to vaccine booster
 One non-responder reported in study (later diagnosed with B-cell Lymphoma)
 Survival following exposure w/o booster
 2010 Liver recipient from rabid donor in Germany
• Vaccinated >20 years prior, anamnestic response
documented
 Reports of significant titer increases following bat
bites among wildlife biologist
 Reduction in rabies cases in Amazonia region of 
Peru after mass childhood immunization campaign
Sabchareon et al. (1998) Ped Inf Dis Journal,  Maier et al (2010) CID, 
PrEP Failure
 1 well documented PrEP failure reported
 1982, Peace Corp Volunteer, Vaccinated ID with HDCV vaccine in Kenya
• Bitten by dog ~6 months later
• Died of rabies 3 months after bite
 Classically attributed to co-administration of chloroquine during PrEP series
• Study at time found other groups give ID HDCV abroad at time had lower or undetectable titers 
compared to those in the US
• Likely multiple causes
 Inadequate response to primary vaccination reported in immunocompromised 
persons 
Bernard et al. (1985) AJTMH
Special Populations – High Risk
 High risk (Continuous and Frequent) categories
 High rate of exposure events, high risk of rabies from exposure
 High titer (>0.5 IU/mL)
• Unrecognized exposure or risk under underappreciated
• Higher titer correlated with protection
 Booster at 6-12 months after primary vaccination improve likelihood of 
maintaining adequate titer
• Reduce frequency of serological monitoring
Special Populations – High Risk
 Moderate risk (Infrequent) category
 High rate of exposure events, low risk of rabies from exposure
 Increased risk sporadic and shortly after primary vaccination (e.g. 
travelers)
• Often limited time to complete vaccination series
 Routine booster at 6-12 months and routine serological 
monitoring not critical
 Adequate anamnestic response expected regardless of titer
 Serology or booster if risk status changes
Special Populations - Immunocompromised
 Data scarce for any schedule
 Risk reduction
 Increased focus on exposure avoidance, appropriate PPE, and prompt health seeking behavior
 Serological confirmation of adequate immune response recommended
 >0.5 IU/mL
Special Populations – Pregnant Women
 No safety concerns reported
 Scarce data
 Risk reduction
 Increased focus on exposure avoidance, appropriate PPE, and prompt health seeking behavior
 May consider deferring where risk reduction possible and PEP readily available
Working Group Plans
 February 2020 ACIP meeting
 Systematic review presentation
 GRADE for 2-dose PrEP schedule
 Future ACIP meetings
 Vote on PrEP schedule
 Additional data for consideration of alternate PEP Schedule
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